Cardinal Health, Inc. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1999, and the six-month period ended on the same date. Cardinal Health, Inc. operates in three segments: Pharmaceutical Distribution, Pharmaceutical Services, and Medical-Surgical Products. The financial statements have been restated to reflect the pooling of interests mergers with Pacific Surgical, Inc. (May 1999) and Automatic Liquid Packaging, Inc. (September 1999).
Key Financial Metrics
| Metric | 3 Months Ended Dec 31, 1999 | 6 Months Ended Dec 31, 1999 |
|---|---|---|
| Total Revenue | $7,399.5 million | $14,183.2 million |
| Net Earnings | $173.5 million | $295.5 million |
| Diluted EPS | $0.61 | $1.03 |
| Gross Margin | $721.9 million (11.54% of operating revenue) | $1,376.7 million (11.39% of operating revenue) |
| Operating Earnings | $301.1 million | $527.8 million |
| Cash and Equivalents | $290.5 million | $290.5 million (Balance Sheet) |
| Working Capital | $2.8 billion | $2.8 billion |
| Commercial Paper Outstanding | $629.9 million | $629.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18% for the quarter and 17% for the six-month period compared to the prior year. Approximately 85% of this growth was driven by existing customers (volume and price increases), with the remainder from new customers.
- Profitability: Net earnings rose 23% for the quarter ($173.5M vs. $141.5M) and 25% for the six-month period ($295.5M vs. $236.2M). Diluted EPS increased from $0.50 to $0.61 for the quarter.
- Margins: Gross margin percentage decreased slightly (11.54% vs. 12.37% for the quarter) due to a higher mix of lower-margin pharmaceutical distribution sales. However, Selling, General, and Administrative (SG&A) expenses as a percentage of revenue improved to 6.64% from 7.59% due to economies of scale.
- Merger Costs: Merger-related costs increased to $5.5 million for the quarter and $42.3 million for the six-month period, compared to $3.1 million and $37.5 million in the prior year, respectively. These costs relate to the integration of ALP, Allegiance, and Scherer.
- Liquidity: Working capital increased to $2.8 billion from $2.2 billion at June 30, 1999, driven by inventory and receivable growth. Commercial paper outstanding rose significantly to $629.9 million from $49.2 million.
Outlook, Risks, and Unusual Items
- Future Merger Costs: Management estimates approximately $91.8 million in additional merger-related costs (net of tax: $58.4 million) will be incurred in future periods, primarily fiscal 2000 and 2001, related to exit costs and integration.
- Legal Proceedings:
- Antitrust Litigation: The Company is a defendant in consolidated class action lawsuits regarding alleged price-fixing. A judgment sharing agreement limits exposure to $1 million or 1% of any judgment. The Seventh Circuit Court of Appeals affirmed the dismissal of the Company, though plaintiffs have petitioned the Supreme Court.
- Latex Glove Litigation: Following the Allegiance merger, the Company faces approximately 486 lawsuits regarding natural rubber latex sensitization. While the Company believes a substantial portion of liability will be covered by insurance, it cannot estimate potential losses as cases have not proceeded to a hearing on the merits.
- Year 2000 Readiness: The Company has incurred approximately $26.4 million in Y2K costs ($7.6 million incremental). No significant system failures have been reported, but the Company notes there can be no assurance that contingency plans will fully mitigate unanticipated risks.
- Segment Performance: Pharmaceutical Distribution revenue grew 25% (quarter) and 23% (six months). Pharmaceutical Services grew 3% due to drug delivery and packaging growth, offset by flat sales in pharmacy automation. Medical-Surgical Products grew 6%.
Investor Verification Checklist
- Verify the impact of the $91.8 million in estimated future merger-related costs on upcoming earnings guidance.
- Monitor the status of the Supreme Court petition regarding the antitrust class action lawsuit to assess potential liability exposure.
- Review the inventory levels ($4.04 billion), which increased significantly due to Y2K preparations and vendor programs, to ensure they align with sales velocity.
- Assess the commercial paper balance ($629.9 million) and interest rate exposure (5.78%) given the increase in short-term debt.
- Confirm the gross margin mix trends, specifically the shift toward lower-margin pharmaceutical distribution and its long-term effect on profitability.